Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Acute Ischemic Stroke Therapeutics Market - Drivers and Forecasts by Technavio

Technavio Research
Posted on: 17 Aug 17

Technavio analysts forecast the global acute ischemic stroke (AIS) therapeutics marketto grow at a CAGR of over 2% during the forecast period, according to their latest report.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005054/en/

Technavio has published a new report on the global acute ischemic stroke therapeutics market from 2017-2021. (Graphic: Business Wire)

The research study covers the present scenario and growth prospects of the global AIS therapeuticsmarketfor 2017-2021. Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

As per the National Institutes of Health (NIH), AIS is the fourth leading cause of death and the most common cause of adult disability in the US. The most common cause of AIS is the obstruction of blood vessels, resulting in decreased oxygen-rich blood supply to a section of the brain, thereby leading to severe damage of neurons. The damaged neurons lead to the corresponding loss of neurological functions, thus requiring immediate medical treatment.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio analysts highlight the following three factors that are contributing to the growth of the global AIS therapeutics market:

  • Rising prevalence of disease
  • Increasing adoption of NOACs
  • Increasing prevalence of sedentary lifestyles

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Rising prevalence of disease

Cardiovascular diseases, particularly MI and stroke, are the leading causes of disability and death globally and are a major public health concern. AIS is the most common form of stroke that occurs when oxygen-rich blood supply to a part of the brain is blocked either by the formation of plaque or a blood clot.

Sapna Jha, a lead cardiovascular and metabolic disorders research analyst at Technavio, says, “With the increasing cases of ischemic stroke, the healthcare community is gaining a better understanding of the pathophysiology of this disease. Additionally, the rise in the prevalence rate and subsequently, the incidence rate of disease, has led to the increase in consumption of AIS therapeutics, such as ACTIVASE, thereby driving the market growth.”

Increasing adoption of NOACs

The increasing adoption of NOACs among physicians is expected to drive the market growth. NOACs, such as dabigatran, rivaroxaban, and apixaban exert their pharmacological effects by either directly targeting thrombin or by inhibiting factor Xa, thereby preventing the formation of thrombus. They provide rapid onset of action and do not require regular coagulation monitoring.

“NOACs are gradually replacing the traditional anticoagulants. Further, with the introduction of anticoagulant antidotes such as idarucizumab in the market, the acceptance of NOACs will increase, as the risk of bleeding will be eliminated. The global AIS therapeutics market is thus shifting from a single injectable anticoagulant to highly competitive NOACs. Some NOACs that are increasingly preferred by physicians include Xarelto from Bayer and Fragmin from Pfizer,” adds Sapna.

Increasing prevalence of sedentary lifestyles

As per the CDC, more than 36% of US adults have obesity. The concept of sedentary lifestyle leading to obesity is no stranger to the global cardiovascular disorders treatment market. The increasing prevalence of cardiovascular diseases in developed and other developing countries can be attributed to the increasing adoption of sedentary lifestyles accompanied by poor diet.

Persistent ischemic condition leads to cell death or apoptosis and the loss of corresponding cell function. For instance, in AIS, ischemia leads to necrosis of neurons and the loss of corresponding neurological function. If not treated on time, it can lead to death. Hence, immediate treatment with AIS therapeutics is required, which, in turn, drives the market growth.

Top vendors:

  • Bayer
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Sanofi

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170817005054/en/

Business Wire
www.businesswire.com

Last updated on: 17/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.